We have located links that may give you full text access.
Diffusion Tensor Imaging for the differential diagnosis of Parkinsonism by machine learning.
Biomedical Journal 2022 June 5
BACKGROUND: There are currently no specific tests for either idiopathic Parkinson's disease or Parkinson-plus syndromes. The study aimed to investigate the diagnostic performance of features extracted from the whole brain using diffusion tensor imaging concerning parkinsonian disorders.
MATERIALS AND METHODS: The retrospective data yielded 625 participants (average age: 61.4±8.2, men/women: 313/312; healthy controls/idiopathic Parkinson's disease/multiple system atrophy/progressive supranuclear palsy: 219/286/51/69) between 2008 and 2017. Diffusion-weighted images were obtained using a 3T MR scanner. The 90th, 50th, and 10th percentiles of fractional anisotropy and mean/axial/radial diffusivity from each parcellated brain area were recorded. Statistical analysis was evaluated based on the features extracted from the whole brain, as determined using discriminant function analysis and support vector machine. 20% of the participants were used as an independent blind dataset with 5 times cross-verification. Diagnostic performance was evaluated by the sensitivity and the F1 score.
RESULTS: Diagnoses were accurate for distinguishing idiopathic Parkinson's disease from healthy control and Parkinson-plus syndromes (87.4±2.1% and 82.5±3.9%, respectively). Diagnostic F1 scores varied for Parkinson-plus syndromes with 67.2±3.8% for multiple system atrophy and 71.6±3.5% for progressive supranuclear palsy. For early and late detection of idiopathic Parkinson's disease, the diagnostic performance was 79.2±7.4% and 84.4±6.9%, respectively. The diagnostic performance was 68.8±11.0% and 52.5±8.9%. in early and late detection to distinguish different Parkinson-plus syndromes.
CONCLUSIONS: Features extracted from diffusion tensor imaging of the whole brain can provide objective evidence for the diagnosis of healthy control, idiopathic Parkinson's disease, and Parkinson-plus syndromes with fair to very good diagnostic performance.
MATERIALS AND METHODS: The retrospective data yielded 625 participants (average age: 61.4±8.2, men/women: 313/312; healthy controls/idiopathic Parkinson's disease/multiple system atrophy/progressive supranuclear palsy: 219/286/51/69) between 2008 and 2017. Diffusion-weighted images were obtained using a 3T MR scanner. The 90th, 50th, and 10th percentiles of fractional anisotropy and mean/axial/radial diffusivity from each parcellated brain area were recorded. Statistical analysis was evaluated based on the features extracted from the whole brain, as determined using discriminant function analysis and support vector machine. 20% of the participants were used as an independent blind dataset with 5 times cross-verification. Diagnostic performance was evaluated by the sensitivity and the F1 score.
RESULTS: Diagnoses were accurate for distinguishing idiopathic Parkinson's disease from healthy control and Parkinson-plus syndromes (87.4±2.1% and 82.5±3.9%, respectively). Diagnostic F1 scores varied for Parkinson-plus syndromes with 67.2±3.8% for multiple system atrophy and 71.6±3.5% for progressive supranuclear palsy. For early and late detection of idiopathic Parkinson's disease, the diagnostic performance was 79.2±7.4% and 84.4±6.9%, respectively. The diagnostic performance was 68.8±11.0% and 52.5±8.9%. in early and late detection to distinguish different Parkinson-plus syndromes.
CONCLUSIONS: Features extracted from diffusion tensor imaging of the whole brain can provide objective evidence for the diagnosis of healthy control, idiopathic Parkinson's disease, and Parkinson-plus syndromes with fair to very good diagnostic performance.
Full text links
Related Resources
Trending Papers
Advances in Clinical Cardiology 2023: A Summary of Key Clinical Trials.Advances in Therapy 2024 May 15
Nutrition in the intensive care unit: from the acute phase to beyond.Intensive Care Medicine 2024 May 22
The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment.Cardiac Failure Review 2024
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.Cochrane Database of Systematic Reviews 2024 May 22
Bronchiectasis management in adults: state of the art and future directions.European Respiratory Journal 2024 May 24
Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review.American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions 2024 April 5
Pathophysiological Link and Treatment Implication of Heart Failure and Preserved Ejection Fraction in Patients with Chronic Kidney Disease.Biomedicines 2024 April 31
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app